These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37864738)

  • 21. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vibration Controlled Transient Elastography to Evaluate Steatosis in Candidate Living Donors for Liver Transplantation.
    Palte E; Duong JK; Remotti H; Burt J; Makkar J; Samstein B; Verna EC; Marratta D; Emond JC; Fox AN
    Transplantation; 2023 Sep; 107(9):1991-1998. PubMed ID: 36959124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled attenuation parameter accurately detects liver steatosis in people with HIV.
    Duarte M; Tien P; Ma Y; Noworolski SM; Korn N; Price JC
    AIDS; 2022 Dec; 36(15):2147-2152. PubMed ID: 35950941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.
    Karlas T; Petroff D; Garnov N; Böhm S; Tenckhoff H; Wittekind C; Wiese M; Schiefke I; Linder N; Schaudinn A; Busse H; Kahn T; Mössner J; Berg T; Tröltzsch M; Keim V; Wiegand J
    PLoS One; 2014; 9(3):e91987. PubMed ID: 24637477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease].
    Goncharov AA; Sasunova AN; Pilipenko VI; Isakov VA
    Ter Arkh; 2023 Oct; 95(8):641-647. PubMed ID: 38158897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis.
    Cai C; Song X; Chen X; Zhou W; Jin Q; Chen S; Ji F
    Can J Gastroenterol Hepatol; 2021; 2021():8859338. PubMed ID: 33542909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
    Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
    World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
    Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD.
    Nogami A; Yoneda M; Iwaki M; Kobayashi T; Kessoku T; Honda Y; Ogawa Y; Imajo K; Higurashi T; Hosono K; Kirikoshi H; Saito S; Nakajima A
    Sci Rep; 2022 Dec; 12(1):21925. PubMed ID: 36535977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
    Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
    Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Pu K; Wang Y; Bai S; Wei H; Zhou Y; Fan J; Qiao L
    BMC Gastroenterol; 2019 Apr; 19(1):51. PubMed ID: 30961539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?
    Trowell J; Alukal J; Zhang T; Liu L; Maheshwari A; Yoo HY; Thuluvath PJ
    Dig Dis Sci; 2021 Apr; 66(4):1297-1305. PubMed ID: 32337667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study.
    Yoo JJ; Yoo YJ; Moon WR; Kim SU; Jeong SW; Park HN; Park MG; Jang JY; Park SY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SG; Kim YS; Kim JH; Yeon JE; Byun KS
    Korean J Intern Med; 2020 Nov; 35(6):1346-1353. PubMed ID: 31694366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
    Singh S; Muir AJ; Dieterich DT; Falck-Ytter YT
    Gastroenterology; 2017 May; 152(6):1544-1577. PubMed ID: 28442120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
    Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.